chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19
Symptoms: Pulmonary thrombosis, Thrombosis
Clinical narrative: Prolonged coughing over a 2 week period; checked at Urgent Care twice, one chest X-ray show nothing. Cough not resolved w' asperator or cough drops. Cough worsens, EMT's called 7/13/21. Emergency Room orders Cat Scan, blood clots found in lungs; MRI finds lots in legs. Patient is a physically fit male, 81. Received Pfizer shots 01/20/21 and 2/10/21. In hospital 5 days, is on oxygen and Xarlto . Follow up w/ primary, Dr could not confirm suspicions that Covid shots caused blood clots.
Sex: U
Vaccine: HEPA
Symptoms: Underdose
Clinical narrative: Administered pediatric Hepatitis A vaccine to Adult
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Head discomfort, Loss of personal independence in daily activities, Neck pain, Posture abnormal
Clinical narrative: My 17 year old daughter got the Pfizer vaccine and has been struggling with heaviness in her head, where she feels like she can't hold her head up; severe neck pain; and seasonal allergy-type symptoms. She has had to miss some school because of it.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Seasonal allergy
Clinical narrative: My 17 year old daughter got the Pfizer vaccine and has been struggling with heaviness in her head, where she feels like she can't hold her head up; severe neck pain; and seasonal allergy-type symptoms. She has had to miss some school because of it.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Endodontic procedure, Fear, Headache, Meningitis, Mobility decreased
Clinical narrative: Nausea, vomiting, arm pain and inability to raise arm for one week, jaw pain and broke tooth that got a clean bill of health from a dentist one week before. Had to have a root canal to repair but no decay found; all from 1st Pfizer covid vaccine 5/19/21 Fever, stiff, neck, headache, Meningitis symptoms and lock jaw from second dose of Pfiser covid vaccine given 6/10/21 Symptoms from 1st dose started within one hr of vaccine. Symptoms from 2nd dose started within 5 days of vaccine and lasted for up to almost 3 weeks. Very afraid of any booster at this point. Had native Covid in Nov 2020 and it wasnt as bad as the side effects of the vaccine.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Nausea, Pain in extremity, Pain in jaw, Pyrexia
Clinical narrative: Nausea, vomiting, arm pain and inability to raise arm for one week, jaw pain and broke tooth that got a clean bill of health from a dentist one week before. Had to have a root canal to repair but no decay found; all from 1st Pfizer covid vaccine 5/19/21 Fever, stiff, neck, headache, Meningitis symptoms and lock jaw from second dose of Pfiser covid vaccine given 6/10/21 Symptoms from 1st dose started within one hr of vaccine. Symptoms from 2nd dose started within 5 days of vaccine and lasted for up to almost 3 weeks. Very afraid of any booster at this point. Had native Covid in Nov 2020 and it wasnt as bad as the side effects of the vaccine.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Tooth fracture, Tooth restoration, Trismus, Vomiting
Clinical narrative: Nausea, vomiting, arm pain and inability to raise arm for one week, jaw pain and broke tooth that got a clean bill of health from a dentist one week before. Had to have a root canal to repair but no decay found; all from 1st Pfizer covid vaccine 5/19/21 Fever, stiff, neck, headache, Meningitis symptoms and lock jaw from second dose of Pfiser covid vaccine given 6/10/21 Symptoms from 1st dose started within one hr of vaccine. Symptoms from 2nd dose started within 5 days of vaccine and lasted for up to almost 3 weeks. Very afraid of any booster at this point. Had native Covid in Nov 2020 and it wasnt as bad as the side effects of the vaccine.
Sex: F
Vaccine: DTAPHEPBIP
Symptoms: Respiratory disorder
Clinical narrative: Respiratory issues; This case was reported by a physician via sales rep and described the occurrence of respiratory disorder in a female patient who received DTPa-HBV-IPV (Pediarix) for prophylaxis.   Co-suspect products included dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received Pediarix and Pediarix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Pediarix and Pediarix Pre-Filled Syringe Device, the patient experienced respiratory disorder. On an unknown date, the outcome of the respiratory disorder was unknown.   It was unknown if the reporter considered the respiratory disorder to be related to Pediarix and Pediarix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not reported. Health care professional reported that the patient experienced respiratory issue after receiving Pediarix. The dates of the event, the lot number or expiration dates were unknown. The health care professional gave permission to be contacted concerning event. The reporter consented to follow up. No further details were known. This case is one of the 10 cases reported by same reporter.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abnormal dreams, Angiogram, Angiogram abnormal, C-reactive protein increased, Catheterisation cardiac normal
Clinical narrative: Myocarditis, 4 day hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Chills, Coxsackie virus test, Dyspnoea, Echocardiogram normal
Clinical narrative: Myocarditis, 4 day hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Electrocardiogram normal, Fatigue, Full blood count normal, Headache, Low density lipoprotein increased
Clinical narrative: Myocarditis, 4 day hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy, Magnetic resonance imaging heart, Malaise, Metabolic function test normal, Mycoplasma test
Clinical narrative: Myocarditis, 4 day hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Myocarditis, Night sweats, Pericardial effusion, Pleuritic pain, Pyrexia
Clinical narrative: Myocarditis, 4 day hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Respiratory viral panel, SARS-CoV-2 test negative, Troponin increased
Clinical narrative: Myocarditis, 4 day hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Myocarditis
Clinical narrative: Myocarditis, 4 day hospitalization
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Chills, Eye pruritus, Headache, Myalgia
Clinical narrative: itchy nose; Skin rash on feet, hands, and breasts; sneezing; itchy eyes; This is a spontaneous report from a contactable nurse (patient). A 27-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiration date not reported), via an unspecified route of administration, administered in Arm Right, on 05Mar2021 10:15 (at the age of 27-year-old), as dose 2, single, for COVID-19 immunisation in hospital. Patient was not pregnant at the time of vaccination. Patient had no known allergies. The patient medical history was not reported. Concomitant medications included ibuprofen; paracetamol (TYLENOL). Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiration date not reported), via an unspecified route of administration, administered in Arm Right, on 12Feb2021 11:00 (at the age of 27-year-old), as dose 1, single, for COVID-19 immunisation in hospital. Patient did not receive other vaccine in four weeks. Patient was not diagnosed with COVID prior vaccination and was not tested COVID post vaccination. The patient experienced skin rash on feet, hands, and breasts, itchy eyes and nose, sneezing on 07Mar2021 09:00. Patient was treated with loratadine due to the events. The outcome of the events was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash pruritic, Sneezing
Clinical narrative: itchy nose; Skin rash on feet, hands, and breasts; sneezing; itchy eyes; This is a spontaneous report from a contactable nurse (patient). A 27-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiration date not reported), via an unspecified route of administration, administered in Arm Right, on 05Mar2021 10:15 (at the age of 27-year-old), as dose 2, single, for COVID-19 immunisation in hospital. Patient was not pregnant at the time of vaccination. Patient had no known allergies. The patient medical history was not reported. Concomitant medications included ibuprofen; paracetamol (TYLENOL). Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiration date not reported), via an unspecified route of administration, administered in Arm Right, on 12Feb2021 11:00 (at the age of 27-year-old), as dose 1, single, for COVID-19 immunisation in hospital. Patient did not receive other vaccine in four weeks. Patient was not diagnosed with COVID prior vaccination and was not tested COVID post vaccination. The patient experienced skin rash on feet, hands, and breasts, itchy eyes and nose, sneezing on 07Mar2021 09:00. Patient was treated with loratadine due to the events. The outcome of the events was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Eye pruritus, Nasal pruritus, Rash, Sneezing
Clinical narrative: itchy nose; Skin rash on feet, hands, and breasts; sneezing; itchy eyes; This is a spontaneous report from a contactable nurse (patient). A 27-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiration date not reported), via an unspecified route of administration, administered in Arm Right, on 05Mar2021 10:15 (at the age of 27-year-old), as dose 2, single, for COVID-19 immunisation in hospital. Patient was not pregnant at the time of vaccination. Patient had no known allergies. The patient medical history was not reported. Concomitant medications included ibuprofen; paracetamol (TYLENOL). Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number and expiration date not reported), via an unspecified route of administration, administered in Arm Right, on 12Feb2021 11:00 (at the age of 27-year-old), as dose 1, single, for COVID-19 immunisation in hospital. Patient did not receive other vaccine in four weeks. Patient was not diagnosed with COVID prior vaccination and was not tested COVID post vaccination. The patient experienced skin rash on feet, hands, and breasts, itchy eyes and nose, sneezing on 07Mar2021 09:00. Patient was treated with loratadine due to the events. The outcome of the events was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Flushing
Clinical narrative: flushing; This is a spontaneous report from a contactable other healthcare professional (HCP). A 62-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 2 intramuscular on 11Feb2021 at 11:00 (Batch/Lot Number: EN6201) as dose 2, single (at the age of 62-years-old) for Covid-19 immunisation. Medical history included diabetes mellitus (DM) and hypertension (HTN) with no known drug allergies (NKDA). The patient's concomitant medications were not reported. It was unknown if the patient had other vaccine in four weeks and if the patient had other medications in two weeks. It was unknown if the patient had Covid prior vaccination, and if the patient tested post vaccination. Approximately 10 minutes after the vaccine was administered, the patient had c/o flushing for approximately 15 minutes. The EMS and Physician on duty assessed the patient and monitored for further symptoms. No treatment was administered for the event. The event resolved on 11Feb2021 at 11:26.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Ear discomfort, Fatigue, Headache, Hot flush
Clinical narrative: inner ear pressure in both ears; dizziness/light-headed; fatigue/ tiredness; weakness; low grade fever; gas; This is a spontaneous report from a contactable consumer or other non hcp. A 30-year-old female patient received bnt162b2 (BNT162B2, solution for injection, Lot Number: EN6204), dose 1 via an unspecified route of administration, administered in Arm Right on 08Mar2021 15:55 (at the age of 30-year-old) as dose 1, single for COVID-19 immunisation. Medical history included juvenile idiopathic arthritis, drug hypersensitivity. Concomitant medication(s) included lamotrigine, oxcarbazepine, mirtazapine, propranolol hydrochloride. The patient previously took septra and experienced drug hypersensitivity. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Adverse event: Approximately 20 minutes after injection, inner ear pressure in both ears, dizziness, light-headed, fatigue, weakness. Three hours after injection, low grade fever, gas and tiredness. On 08Mar2021 16:15, the patient experienced inner ear pressure in both ears, dizziness/light-headed, fatigue/ tiredness, weakness and three hours after injection, patient experienced low grade fever, gas. The outcome of all the events was not recovered.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Muscle tightness, Pain in extremity, Pyrexia, Vitreous floaters
Clinical narrative: inner ear pressure in both ears; dizziness/light-headed; fatigue/ tiredness; weakness; low grade fever; gas; This is a spontaneous report from a contactable consumer or other non hcp. A 30-year-old female patient received bnt162b2 (BNT162B2, solution for injection, Lot Number: EN6204), dose 1 via an unspecified route of administration, administered in Arm Right on 08Mar2021 15:55 (at the age of 30-year-old) as dose 1, single for COVID-19 immunisation. Medical history included juvenile idiopathic arthritis, drug hypersensitivity. Concomitant medication(s) included lamotrigine, oxcarbazepine, mirtazapine, propranolol hydrochloride. The patient previously took septra and experienced drug hypersensitivity. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Adverse event: Approximately 20 minutes after injection, inner ear pressure in both ears, dizziness, light-headed, fatigue, weakness. Three hours after injection, low grade fever, gas and tiredness. On 08Mar2021 16:15, the patient experienced inner ear pressure in both ears, dizziness/light-headed, fatigue/ tiredness, weakness and three hours after injection, patient experienced low grade fever, gas. The outcome of all the events was not recovered.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Dizziness, Ear discomfort, Fatigue, Flatulence
Clinical narrative: inner ear pressure in both ears; dizziness/light-headed; fatigue/ tiredness; weakness; low grade fever; gas; This is a spontaneous report from a contactable consumer or other non hcp. A 30-year-old female patient received bnt162b2 (BNT162B2, solution for injection, Lot Number: EN6204), dose 1 via an unspecified route of administration, administered in Arm Right on 08Mar2021 15:55 (at the age of 30-year-old) as dose 1, single for COVID-19 immunisation. Medical history included juvenile idiopathic arthritis, drug hypersensitivity. Concomitant medication(s) included lamotrigine, oxcarbazepine, mirtazapine, propranolol hydrochloride. The patient previously took septra and experienced drug hypersensitivity. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Adverse event: Approximately 20 minutes after injection, inner ear pressure in both ears, dizziness, light-headed, fatigue, weakness. Three hours after injection, low grade fever, gas and tiredness. On 08Mar2021 16:15, the patient experienced inner ear pressure in both ears, dizziness/light-headed, fatigue/ tiredness, weakness and three hours after injection, patient experienced low grade fever, gas. The outcome of all the events was not recovered.   No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia
Clinical narrative: inner ear pressure in both ears; dizziness/light-headed; fatigue/ tiredness; weakness; low grade fever; gas; This is a spontaneous report from a contactable consumer or other non hcp. A 30-year-old female patient received bnt162b2 (BNT162B2, solution for injection, Lot Number: EN6204), dose 1 via an unspecified route of administration, administered in Arm Right on 08Mar2021 15:55 (at the age of 30-year-old) as dose 1, single for COVID-19 immunisation. Medical history included juvenile idiopathic arthritis, drug hypersensitivity. Concomitant medication(s) included lamotrigine, oxcarbazepine, mirtazapine, propranolol hydrochloride. The patient previously took septra and experienced drug hypersensitivity. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Adverse event: Approximately 20 minutes after injection, inner ear pressure in both ears, dizziness, light-headed, fatigue, weakness. Three hours after injection, low grade fever, gas and tiredness. On 08Mar2021 16:15, the patient experienced inner ear pressure in both ears, dizziness/light-headed, fatigue/ tiredness, weakness and three hours after injection, patient experienced low grade fever, gas. The outcome of all the events was not recovered.   No follow-up attempts are possible. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Disorientation, Dizziness, Oxygen saturation decreased, Seizure
Clinical narrative: Had stroke like symptoms. Confusion and vomiting seizure symptoms before medics were called. Low oxygen and immediately taking by squad to hospital
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Biopsy, Computerised tomogram, Confusional state, Magnetic resonance imaging, Neurological symptom
Clinical narrative: Had stroke like symptoms. Confusion and vomiting seizure symptoms before medics were called. Low oxygen and immediately taking by squad to hospital
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Oxygen saturation decreased, Seizure like phenomena, Vomiting
Clinical narrative: Had stroke like symptoms. Confusion and vomiting seizure symptoms before medics were called. Low oxygen and immediately taking by squad to hospital
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Pharyngeal swelling
Clinical narrative: Patient consumed 50 mg PO of her  personal Benadryl prior to vaccine administration, but still feels like her breathing is labored. Sat with patient to provide comfort and requested PA, for assistance. Patient, wife, and PA in agreement to transport to the ER per patient's history. EMS phoned & patient transported to
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea
Clinical narrative: Patient consumed 50 mg PO of her  personal Benadryl prior to vaccine administration, but still feels like her breathing is labored. Sat with patient to provide comfort and requested PA, for assistance. Patient, wife, and PA in agreement to transport to the ER per patient's history. EMS phoned & patient transported to
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Arthralgia, Back pain, Body temperature increased, Chest discomfort, Chest pain
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Chills, Cold sweat, Discomfort, Dyspnoea, Echocardiogram abnormal
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Ejection fraction decreased, Electrocardiogram abnormal, Headache, Liver function test increased, Malaise
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Pain, Pain in extremity, Pericarditis, Pyrexia, Troponin
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Wall motion score index abnormal
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram, Arthralgia, Back pain, Chest pain, Chills
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Dyspnoea, Ejection fraction, Ejection fraction decreased, Electrocardiogram, Headache
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Myocarditis, Pain, Pain in extremity, Pyrexia, SARS-CoV-2 test
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Troponin, Troponin increased, Ultrasound scan, Vital signs measurement
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram normal, Cardiac imaging procedure abnormal, Chest pain, Dyspnoea, Echocardiogram
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Electrocardiogram abnormal, Myocarditis, Troponin increased, Ultrasound scan abnormal
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Myocarditis
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Ejection fraction, Myocarditis, Troponin I
Clinical narrative: Myocarditis resulting in hospitalization
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Arthralgia, Back pain, Body temperature increased, Chest discomfort, Chest pain
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Chills, Cold sweat, Discomfort, Dyspnoea, Echocardiogram abnormal
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Ejection fraction decreased, Electrocardiogram abnormal, Headache, Liver function test increased, Malaise
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Pain, Pain in extremity, Pericarditis, Pyrexia, Troponin
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Wall motion score index abnormal
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram, Arthralgia, Back pain, Chest pain, Chills
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Dyspnoea, Ejection fraction, Ejection fraction decreased, Electrocardiogram, Headache
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Myocarditis, Pain, Pain in extremity, Pyrexia, SARS-CoV-2 test
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Troponin, Troponin increased, Ultrasound scan, Vital signs measurement
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram normal, Cardiac imaging procedure abnormal, Chest pain, Dyspnoea, Echocardiogram
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Electrocardiogram abnormal, Myocarditis, Troponin increased, Ultrasound scan abnormal
Clinical narrative: Myocarditis; This literature-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (Myocarditis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDITIS (Myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (Myocarditis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ejection fraction: 52 % (normal) 52 %. On an unknown date, Troponin I: 13 ng/ml (High) 13 ng/mL.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (Myocarditis) to be possibly related.    No concomitant medication was reported.  This analysis shows that myocarditis related to COVID-19 vaccine has an overall fast recovery with no short-term complications. Out of 15 patient 1 patient had subtle apical septal and apical lateral hypokinesis with a LVEF of 52%.  No treatment medication was reported  This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.   This case was linked to MOD-2021-317848, MOD-2021-317975, MOD-2021-317977, MOD-2021-317978 (Patient Link).; Sender's Comments: This literature-study case was reported in a literature article and describes the occurrence of Myocarditis in a 39-year-old male patient who received both dosis of mRNA-1273. Based on reporter´s causality , a causal relationship cannot be excluded.